Abstract: The invention relates to a dermal flowable-composition dispenser that includes a body for retaining a supply of the composition, an application portion having an application surface, and a conduit connecting the supply chamber with the application surface for facilitating the reproducible delivery of a predetermined dose of the composition to the application surface. The application surface includes a concave application surface and a front side having an upper rim enclosing the application surface and forming a depression that has a volume that is greater than or equal to the volume of the predetermine dose. Also, the application surface is configured and dimensioned such it can receive the patient's skin to allow for removal of the predetermined dose of the composition, and wherein the concave application surface is shaped such that the entire application surface contacts the patient's skin when the application surface is pressed thereagainst.

Abstract: The present invention comprises non occlusive compositions for transdermal delivery of nicotine, and more particularly pharmaceutically acceptable salts thereof, and methods of making same. The composition may, for example, be a gel suitable for transdermal or transmucosal applications. The compositions of the present invention typically comprise a mixture of water and alcohol, and a solvent system having a mono alkyl ether of diethylene glycol and a glycol present in specified ratios and in specific amounts, wherein the pH of the gel is usually between a pH of 5.5 and 7. The compositions may include further components, for example, the hydroalcoholic vehicle may further comprise additional penetration enhancer(s), buffering agent(s), antioxidant(s), stabilizer(s) and/or gelling agent(s). The invention also relates to a method for the sustained delivery of nicotine pharmaceutically acceptable salts to treat a variety of conditions and disorders.

Abstract: This invention relates to novel transdermal or transmucosal pharmaceutical formulation which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The novel formulation includes at least one pharmacologically active ingredient, and a solvent system having a monoalkylether of diethylene glycol and a glycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of an active agent in a pharmaceutical formulation.